Letter to the editorSarcoidosis: An underestimated and potentially severe side effect of anti-TNF-alpha therapy
Section snippets
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
References (10)
- et al.
Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues
Clin Immunol
(2011) - et al.
TNFα: activator or inhibitor of regulatory T cells?
Joint Bone Spine
(2012) - et al.
Paradoxical cutaneous manifestations during anti-TNF therapy
Joint Bone Spine
(2010) - et al.
Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases
Am J Med
(2011) - et al.
Sarcoidosis
N Engl J Med
(2007)
There are more references available in the full text version of this article.
Cited by (43)
Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis
2019, Revue du Rhumatisme (Edition Francaise)Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis
2018, Joint Bone SpineParadoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature
2018, Actas Dermo-SifiliograficasUltrasound characterization of ankle involvement in Löfgren syndrome
2018, Revue du Rhumatisme (Edition Francaise)Drug-Induced Sarcoidosis-Like Reactions
2018, ChestCitation Excerpt :Unlike sarcoidosis, DISRs often resolve after discontinuation of the offending agent, and may recur with rechallenge; these may be the only features that reliably distinguish these two entities. A list of drugs clearly associated with DISRs is shown in Table 1.3,4,6,7,10,12,15-145 In Figure 1, a case of a DISR is shown.
Ocular sarcoidosis: What the internist should know?
2018, Revue de Medecine Interne
Copyright © 2012 Société française de rhumatologie. Published by Elsevier Masson SAS All rights reserved.